Aligos Therapeutics Secures License Agreement for Pevifoscorvir Sodium
Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company focused on liver and viral diseases, announced on April 16, 2026, that it has entered into an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. to develop and commercialize pevifoscorvir sodium in Greater China, which includes Mainland China, Taiwan, Hong Kong, and Macau, for chronic hepatitis B virus infection. Under the terms of the agreement, Aligos will receive an upfront milestone payment of $25 million USD and is eligible for up to $420 million USD in additional clinical, regulatory, and sales milestones, along with tiered, high single-digit royalties on net sales in the licensed territories, according to GlobeNewswire PE.
Details of the Agreement
Aligos retains all development and commercialization rights for pevifoscorvir sodium in the United States, Europe, South Korea, Japan, and other markets, while also maintaining the right to conduct clinical trials in Greater China. With more than 90 million people living with HBV in Greater China and Amoytop’s leadership in the Mainland China hepatology market, the agreement positions pevifoscorvir sodium for development in the region. As a result, Aligos expects its current cash, cash equivalents, and investments to extend into the fourth quarter of 2026 based on the current operating plan.
Company Background and Partnership
Aligos, led by Chairman, President, and CEO Lawrence Blatt, Ph.D., MBA, has an established relationship with Amoytop through their preclinical antisense oligonucleotide program, ALG-170675, for chronic HBV infection. Amoytop, as the leading provider of pegylated interferon for chronic HBV in Mainland China, has a robust commercial organization with sales representatives focused on the hepatology field, which is expected to accelerate the development of pevifoscorvir sodium in the region. Aligos currently intends to combine pevifoscorvir sodium with Amoytop’s drug PEGBING® and their ongoing ASO collaboration to enable differentiated combination regimens for patients with chronic HBV infection across Greater China, according to GlobeNewswire PE. As widely-known context, chronic hepatitis B remains a significant global health challenge affecting millions worldwide, though this deal focuses specifically on the Greater China region.
Future Development Plans
Aligos plans to pursue strategies for chronic HBV suppression, including combining pevifoscorvir sodium with other treatments, while leveraging Amoytop’s expertise in the Mainland China hepatology market for broader adoption. Amoytop’s strong reach is anticipated to support the drug’s development compared to Aligos handling it alone in the region. This agreement builds on their prior collaboration and aligns with Aligos’s focus on addressing unmet needs in viral diseases, according to GlobeNewswire PE.
